Summit has announced additional data from its Phase II CoDIFy trial of ridinilazole for the treatment of C. difficile infection, showing that ridinilazole’s statistically superior sustained clinical response over vancomycin was driven by a marked reduction in recurrence of the infection. C. difficle infection is established as a major healthcare threat, with around 900,000 cases per annum in Europe and North America. Recurrent disease represents a key clinical issue with up to 25% of patients at ....
